On November 8, 2021 Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the Company has filed for Breakthrough Therapy designation (BTD) with the U.S. Food and Drug Administration (FDA) for the use of its lead investigational candidate in chemoradiation-induced oral mucositis (CRIOM) (Press release, Enzychem Lifesciences, NOV 8, 2021, View Source [SID1234594750]). The BTD filing is based on data from the Company’s Phase 2 trial.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
FDA Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).
"We are very pleased to file the FDA breakthrough therapy designation for EC-18 in CRIOM, as it will enable us to work closely with FDA on our potential design of our Phase 3 program," said Ki Young Sohn, Chairman and Chief Executive Officer of Enzychem Lifesciences. "This designation underscores a recognition of the urgent need to bring novel treatments to CRIOM patients who have a debilitating side-effect of chemoradiation therapy. As a novel, first-in-class small molecule drug, we believe that EC-18 has the potential to be an important treatment option for cancer patients undergoing chemoradiation therapy with currently no approved therapies for CRIOM."
Phase 2, randomized, double-blind, placebo-controlled, 2-stage study evaluated EC-18 for Head and Neck Cancer patients with squamous cell cancers of the mouth, oropharynx, hypopharynx and nasopharynx who received standard fractionated intensity-modulated radiotherapy with concomitant chemotherapy (cisplatin). For Stage 2 of the study, 80 patients were randomized into a 1:1 scheme to receive either placebo or 2000 mg of EC-18 as the maximum tolerable dose, determined by the independent Data Safety Monitoring Board in Stage 1.
CRIOM is an acute inflammation of the oral mucosa following systemic chemoradiation therapy. It can lead to several problems, including pain, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa. The symptoms have a significant effect on the patient’s quality of life and can limit the doses and duration of cancer treatment, leading to sub-optimal treatment.